Florbetaben PET in the early diagnosis of alzheimer's disease: A discrete event simulation to explore its potential value and key data gaps

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Guo, Shien ^a   Getsios, Denis ^a   Hernandez, Luis ^a   Cho, Kelly ^b,c   Lawler, Elizabeth ^b,c,d   Altincatal, Arman ^a,b   Lanes, Stephan ^a   Blankenburg, Michael ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; FLORBETABEN; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84872774804     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/548157     Document Type: Article

References (44)

1. Cummings J. L., Alzheimer's disease. The New England Journal of Medicine 2004 351 1 56 67 2-s2.0-3042857903 10.1056/NEJMra040223 (Pubitemid 38857248)
2. Kochanek K. D., Xu J., Murphy S. L., Deaths: preliminary data for 2009. National Center for Health Statistics 2011 59 4
3. Wimo A., Winblad B., Jönsson L., The worldwide societal costs of dementia: estimates for 2009. Alzheimer's and Dementia 2010 6 2 98 103 2-s2.0-77949335521 10.1016/j.jalz.2010.01.010
4. Birks J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006 1 CD005593 2-s2.0-33645524717
5. Hansen R. A., Gartlehner G., Webb A. P., Morgan L. C., Moore C. G., Jonas D. E., Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical Interventions in Aging 2008 3 2 211 225 2-s2.0-47849119964 (Pubitemid 352037861)
6. Banarjee S., Wittenberg R., Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. International Journal of Geriatric Psychiatry 2009 24 7 748 754 2-s2.0-67649386695 10.1002/gps.2191
7. Getsios D., Blume S., Ishak K. J., Maclaine G., Hernández L., An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimer's and Dementia 2012 8 1 22 30 2-s2.0-79952591563 10.1016/j.jalz.2010.07.001
8. Löppönen M., Räiha I., Isoaho R., Vahlberg T., Kivelä S. L., Diagnosing cognitive impairment and dementia in primary health care-a more active approach is needed. Age and Ageing 2003 32 6 606 612 2-s2.0-0344034779 10.1093/ageing/afg097 (Pubitemid 37461568)
9. Ranginwala N. A., Hynan L. S., Weiner M. F., White C. L., Clinical criteria for the diagnosis of alzheimer disease: still good after all these years. American Journal of Geriatric Psychiatry 2008 16 5 384 388 2-s2.0-48649092771 10.1097/JGP.0b013e3181629971
10. Taylor D. H. Jr., Østbye T., Langa K. M., Weir D., Plassman B. L., The accuracy of medicare claims as an epidemiological tool: the case of dementia revisited. Journal of Alzheimer's Disease 2009 17 4 807 815 2-s2.0-68949161698 10.3233/JAD-2009-1099
11. Bloudek L. M., Spackman D. E., Blankenburg M., Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. Journal of Alzheimer's Disease 2011 26 4 627 645
12. Dubois B., Feldman H. H., Jacova C., Cummings J. L., DeKosky S. T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N. C., Galasko D., Gauthier S., Hampel H., Jicha G. A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L. C., Stern Y., Visser P. J., Scheltens P., Revising the definition of Alzheimer's disease: a new lexicon. The Lancet Neurology 2010 9 11 1118 1127 2-s2.0-77957951112 10.1016/S1474-4422(10) 70223-4
13. Barthel H., Gertz H. J., Dresel S., Peters O., Bartenstein P., Buerger K., Hiemeyer F., Wittemer-Rump S. M., Seibyl J., Reininger C., Sabri O., Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. The Lancet Neurology 2011 10 5 424 435 2-s2.0-79954748692 10.1016/S1474-4422(11) 70077-1
14. Barthel H., Luthardt J., Becker G., Patt M., Hammerstein E., Hartwig K., Eggers B., Sattler B., Schildan A., Hesse S., Meyer P. M., Wolf H., Zimmermann T., Reischl J., Rohde B., Gertz H. J., Reininger C., Sabri O., Individualized quantification of brain β -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 9 1702 1714 2-s2.0-79955493891 10.1007/s00259-011-1821-1
15. Villemagne V. L., Ong K., Mulligan R. S., Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine 2010 52 8 1210 1217
16. Center for Medicare and Medicaid Services, Hospital Outpatient File PPS Payment Rate 2011
17. Center for Medicare and Medicaid Services, Clinical Diagnostic Laboratory Fee Schedule 2011
18. Center for Medicare and Medicaid Services, CMS Physician Fee Schedule 2011
19. Red Book, Red Book For Windows 2011,060 2011
20. Zhu C. W., Leibman C., McLaughlin T., Zbrozek A. S., Scarmeas N., Albert M., Brandt J., Blacker D., Sano M., Stern Y., Patient dependence and longitudinal changes in costs of care in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2008 26 5 416 423 2-s2.0-54149116942 10.1159/000164797
21. Hill J., Fillit H., Shah S. N., del Valle M. C., Futterman R., Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population. Journal of Alzheimer's Disease 2005 8 1 43 50 2-s2.0-24644464294 (Pubitemid 41267322)
22. Center for Medicare and Medicaid Services, Healthcare financing review. 2010 Statistical Supplement 2010
23. US Department of Labor,. Federal minimal wage, 2011, http://www.dol.gov
24. Caro J. J., Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 2005 23 4 323 332 2-s2.0-18744388870 10.2165/00019053- 200523040-00003 (Pubitemid 40677051)
25. Getsios D., Blume S., Ishak K. J., Maclaine G. D. H., Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. PharmacoEconomics 2010 28 5 411 427 2-s2.0-77951443851 10.2165/11531870-000000000-00000
26. Guo S., Hernandez L., Wasiak R., Gaudig M., Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany. Journal of Medical Economics 2010 13 4 641 654 2-s2.0-78650057940 10.3111/13696998.2010.528101
27. Lipscome J., Weinstein M. C., Torrance G. W., Gold M. R., Siegel J. E., Russell L. B., Time preference. Cost-Effectiveness in Health and Medicine 1996 New York Oxford University Press
28. National Institute for Health and Clinical Excellence, Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. 2006, http://www.nice.org.uk/
29. Ganguli M., Dodge H. H., Shen C., DeKosky S. T., Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004 63 1 115 121 2-s2.0-3242716703 (Pubitemid 38943788)
30. Plassman B. L., Langa K. M., Fisher G. G., Heeringa S. G., Weir D. R., Ofstedal M. B., Burke J. R., Hurd M. D., Potter G. G., Rodgers W. L., Steffens D. C., Willis R. J., Wallace R. B., Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007 29 1-2 125 132 2-s2.0-36549073145 10.1159/000109998 (Pubitemid 350191430)
31. Schultz J., Joish V., Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatric Services 2009 60 12 1604 1611 2-s2.0-71549140081 10.1176/appi.ps.60.12.1604
32. Ballard C., O'Brien J., Morris C. M., Barber R., Swann A., Neill D., McKeith I., The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry 2001 16 5 499 503 2-s2.0-0035013468 10.1002/gps.381 (Pubitemid 32492384)
33. Hanyu H., Sato T., Hirao K., Kanetaka H., Sakurai H., Iwamoto T., Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. European Journal of Neurology 2009 16 2 212 217 2-s2.0-58349114729 10.1111/j.1468-1331.2008.02388.x
34. Rascovsky K., Salmon D. P., Lipton A. M., Leverenz J. B., Decarli C., Jagust W. J., Clark C. M., Mendez M. F., Tang-Wai D. F., Graff-Radford N. R., Galasko D., Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005 65 3 397 403 2-s2.0-23244452355 10.1212/01.wnl. 0000171343.43314.6e (Pubitemid 41099802)
35. Williams M. M., Xiong C., Morris J. C., Galvin J. E., Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 2006 67 11 1935 1941 2-s2.0-33845694258 10.1212/01.wnl.0000247041. 63081.98 (Pubitemid 44967367)
36. Kochanek K. D., Xu J., Murphy S. L.,. 2009 US Life Table, March, 2011
37. Wilson R. S., Aggarwal N. T., Barnes L. L., Bienias J. L., Mendes De Leon C. F., Evans D. A., Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Archives of Neurology 2009 66 6 767 772 2-s2.0-67049095861 10.1001/archneurol.2009.80
38. Jönsson L., Andreasen N., Kilander L., Soininen H., Waldemar G., Nygaard H., Winblad B., Jönhagen M. E., Hallikainen M., Wimo A., Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Disease and Associated Disorders 2006 20 1 49 55 2-s2.0-33745657911 10.1097/01.wad.0000201851.52707.c9 (Pubitemid 44356894)
39. Andersen C. K., Wittrup-Jensen K. U., Lolk A., Andersen K., Kragh-Sørensen P., Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health and Quality of Life Outcomes 2004 2, article 52 2-s2.0-16244381254 10.1186/1477-7525-2-52 (Pubitemid 40472030)
40. Ekman M., Berg J., Wimo A., Jönsson L., McBurney C., Health utilities in mild cognitive impairment and dementia: a population study in Sweden. International Journal of Geriatric Psychiatry 2007 22 7 649 655 2-s2.0-34547513759 10.1002/gps.1725 (Pubitemid 47180377)
41. Schipke C. G., Peters O., Heuser I., Impact of beta-amyloid-specific Florbetaben PET imaging on early diagnosis and patient management in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2012 33 6 416 422
42. Neumann P. J., Cohen J. T., Hammitt J. K., Concannon T. W., Auerbach H. R., Fang C., Kent D. M., Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics 2012 21 3 238 251 2-s2.0-84856333006 10.1002/hec.1704
43. Neumann P. J., Hammitt J. K., Mueller C., Fillit H. M., Hill J., Tetteh N. A., Kosik K. S., Public attitudes about genetic testing for alzheimer's disease. Health Affairs 2001 20 5 252 264 2-s2.0-0035461637 (Pubitemid 33710358)
44. Luppa M., Heinrich S., Matschinger H., Sandholzer H., Angermeyer M. C., Konig H. H., Direct costs associated with depression in old age in Germany. Journal of Affective Disorders 2008 105 1-3 195 204 10.1016/j.jad.2007.05.008 (Pubitemid 350236364)